Clinical trial DS8201-A-U303
A phase 3, multicenter, randomized, open-label, active-controlled trial of DS-8201a, an anti-HER2-antibody drug conjugate (ADC), versus treatment of Physician's choice for HER2-low, HR-positive, unresectable and/or metastatic breast cancer subjects (DS8201-A-U303)
| Cancers | |
|---|---|
| Organ | Breast |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Daiichi Sankyo |
| EudraCT Identifier | 2018-003069-33 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03734029 |
| Inclusion criteria | HER2 low (+ or ++)/ER+ or ER-. Metastatic |
| Last update |